Dysregulated recruitment of the histone methyltransferase EZH2 to the class II transactivator (CIITA) promoter IV in breast cancer cells

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Truax, Agnieszka D ^a   Thakkar, Meghna ^a   Greer, Susanna F ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLASS 2 TRANSACTIVATOR PROTEIN; GAMMA INTERFERON; HISTONE H3; HISTONE H4; LYSINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; EZH2 PROTEIN, HUMAN; HISTONE; HLA DR ANTIGEN; MHC CLASS II TRANSACTIVATOR PROTEIN; NUCLEAR PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; C2TA GENE; CANCER CELL CULTURE; CANCER GROWTH; CONTROLLED STUDY; DNA METHYLATION; DNA MODIFICATION; EPIGENETICS; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE SILENCING; HISTONE ACETYLATION; HLA DR GENE; HUMAN; HUMAN CELL; METASTASIS; ONCOGENE; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION REGULATION; TRANSCRIPTION TERMINATION; TUMOR ESCAPE; ACETYLATION; BREAST TUMOR; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GENETICS; METABOLISM; METHYLATION; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROTEIN BINDING; RNA INTERFERENCE; TUMOR CELL LINE;

ACETYLATION; BASE SEQUENCE; BREAST NEOPLASMS; CELL LINE, TUMOR; DNA-BINDING PROTEINS; FEMALE; HISTONES; HLA-DR ALPHA-CHAINS; HUMANS; INTERFERON-GAMMA; METHYLATION; MOLECULAR SEQUENCE DATA; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS;

EID: 84860378152     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0036013     Document Type: Article

References (72)

1. Kaufman JF, Auffray C, Korman AJ, Shackelford DA, Strominger J, (1984) The class II molecules of the human and murine major histocompatibility complex. Cell 36: 1-13.
2. Chang CH, Fontes JD, Peterlin M, Flavell RA, (1994) Class II transactivator (CIITA) is sufficient for the inducible expression of major histocompatibility complex class II genes. J Exp Med 180: 1367-1374.
3. Langlade-Demoyen P, Garcia-Pons F, Castiglioni P, Garcia Z, Cardinaud S, et al. (2003) Role of T cell help and endoplasmic reticulum targeting in protective CTL response against influenza virus. Eur J Immunol 33: 720-728.
4. Greenberg PD, Cheever MA, Fefer A, (1981) Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes. J Exp Med 154: 952-963.
5. Fujiwara H, Fukuzawa M, Yoshioka T, Nakajima H, Hamaoka T, (1984) The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity. J Immunol 133: 1671-1676.
6. Hock H, Dorsch M, Diamantstein T, Blankenstein T, (1991) Interleukin 7 induces CD4+ T cell-dependent tumor rejection. J Exp Med 174: 1291-1298.
7. Lauritzsen GF, Weiss S, Dembic Z, Bogen B, (1994) Naive idiotype-specific CD4+ T cells and immunosurveillance of B-cell tumors. Proc Natl Acad Sci U S A 91: 5700-5704.
8. Warabi M, Kitagawa M, Hirokawa K, (2000) Loss of MHC class II expression is associated with a decrease of tumor-infiltrating T cells and an increase of metastatic potential of colorectal cancer: immunohistological and histopathological analyses as compared with normal colonic mucosa and adenomas. Pathol Res Pract 196: 807-815.
9. Garrido F, Ruiz-Cabello F, (1991) MHC expression on human tumors-its relevance for local tumor growth and metastasis. Semin Cancer Biol 2: 3-10.
10. Ting JP, Trowsdale J, (2002) Genetic control of MHC class II expression. Cell 109 (Suppl): S21-33.
11. Boss JM, (1997) Regulation of transcription of MHC class II genes. Curr Opin Immunol 9: 107-113.
12. Fontes JD, Jiang B, Peterlin BM, (1997) The class II trans-activator CIITA interacts with the TBP-associated factor TAFII32. Nucleic Acids Res 25: 2522-2528.
13. Mahanta SK, Scholl T, Yang FC, Strominger JL, (1997) Transactivation by CIITA, the type II bare lymphocyte syndrome-associated factor, requires participation of multiple regions of the TATA box binding protein. Proc Natl Acad Sci U S A 94: 6324-6329.
14. Drozina G, Kohoutek J, Jabrane-Ferrat N, Peterlin BM, (2005) Expression of MHC II genes. Curr Top Microbiol Immunol 290: 147-170.
15. Beresford GW, Boss JM, (2001) CIITA coordinates multiple histone acetylation modifications at the HLA-DRA promoter. Nat Immunol 2: 652-657.
16. Fontes JD, Kanazawa S, Jean D, Peterlin BM, (1999) Interactions between the class II transactivator and CREB binding protein increase transcription of major histocompatibility complex class II genes. Mol Cell Biol 19: 941-947.
17. Zika E, Greer SF, Zhu XS, Ting JP, (2003) Histone deacetylase 1/mSin3A disrupts gamma interferon-induced CIITA function and major histocompatibility complex class II enhanceosome formation. Mol Cell Biol 23: 3091-3102.
18. Muhlethaler-Mottet A, Krawczyk M, Masternak K, Spilianakis C, Kretsovali A, et al. (2004) The S box of major histocompatibility complex class II promoters is a key determinant for recruitment of the transcriptional co-activator CIITA. J Biol Chem 279: 40529-40535.
19. Spilianakis C, Kretsovali A, Agalioti T, Makatounakis T, Thanos D, et al. (2003) CIITA regulates transcription onset viaSer5-phosphorylation of RNA Pol II. Embo J 22: 5125-5136.
20. Muhlethaler-Mottet A, Otten LA, Steimle V, Mach B, (1997) Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA. Embo J 16: 2851-2860.
21. Pai RK, Askew D, Boom WH, Harding CV, (2002) Regulation of class II MHC expression in APCs: roles of types I, III, and IV class II transactivator. J Immunol 169: 1326-1333.
22. Landmann S, Muhlethaler-Mottet A, Bernasconi L, Suter T, Waldburger JM, et al. (2001) Maturation of dendritic cells is accompanied by rapid transcriptional silencing of class II transactivator (CIITA) expression. J Exp Med 194: 379-391.
23. Lennon AM, Ottone C, Rigaud G, Deaven LL, Longmire J, et al. (1997) Isolation of a B-cell-specific promoter for the human class II transactivator. Immunogenetics 45: 266-273.
24. Piskurich JF, Gilbert CA, Ashley BD, Zhao M, Chen H, et al. (2006) Expression of the MHC class II transactivator (CIITA) type IV promoter in B lymphocytes and regulation by IFN-gamma. Mol Immunol 43: 519-528.
25. Piskurich JF, Linhoff MW, Wang Y, Ting JP, (1999) Two distinct gamma interferon-inducible promoters of the major histocompatibility complex class II transactivator gene are differentially regulated by STAT1, interferon regulatory factor 1, and transforming growth factor beta. Mol Cell Biol 19: 431-440.
26. Muhlethaler-Mottet A, Di Berardino W, Otten LA, Mach B, (1998) Activation of the MHC class II transactivator CIITA by interferon-gamma requires cooperative interaction between Stat1 and USF-1. Immunity 8: 157-166.
27. Koues OI, Dudley RK, Truax AD, Gerhardt D, Bhat KP, et al. (2008) Regulation of acetylation at the major histocompatibility complex class II proximal promoter by the 19S proteasomal ATPase Sug1. Mol Cell Biol 28: 5837-5850.
28. Truax AD, Koues OI, Mentel MK, Greer SF, (2010) The 19S ATPase S6a (S6′/TBP1) regulates the transcription initiation of class II transactivator. J Mol Biol 395: 254-269.
29. Mehta NT, Truax AD, Boyd NH, Greer SF, (2011) Early epigenetic events regulate the adaptive immune response gene CIITA. Epigenetics 6.
30. Wright KL, Ting JP, (2006) Epigenetic regulation of MHC-II and CIITA genes. Trends Immunol 27: 405-412.
31. Agalioti T, Chen G, Thanos D, (2002) Deciphering the transcriptional histone acetylation code for a human gene. Cell 111: 381-392.
32. Morris AC, Beresford GW, Mooney MR, Boss JM, (2002) Kinetics of a gamma interferon response: expression and assembly of CIITA promoter IV and inhibition by methylation. Mol Cell Biol 22: 4781-4791.
33. Ni Z, Karaskov E, Yu T, Callaghan SM, Der S, et al. (2005) Apical role for BRG1 in cytokine-induced promoter assembly. Proc Natl Acad Sci U S A 102: 14611-14616.
34. Holling TM, Bergevoet MW, Wilson L, Van Eggermond MC, Schooten E, et al. (2007) A role for EZH2 in silencing of IFN-gamma inducible MHC2TA transcription in uveal melanoma. J Immunol 179: 5317-5325.
35. Holling TM, van Eggermond MC, Jager MJ, van den Elsen PJ, (2006) Epigenetic silencing of MHC2TA transcription in cancer. Biochem Pharmacol 72: 1570-1576.
36. Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, et al. (2002) Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 298: 1039-1043.
37. Cao R, Zhang Y, (2004) The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr Opin Genet Dev 14: 155-164.
38. Kuzmichev A, Nishioka K, Erdjument-Bromage H, Tempst P, Reinberg D, (2002) Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. Genes Dev 16: 2893-2905.
39. Dadmarz R, Sgagias MK, Rosenberg SA, Schwartzentruber DJ, (1995) CD4+ T lymphocytes infiltrating human breast cancer recognise autologous tumor in an MHC-class-II restricted fashion. Cancer Immunol Immunother 40: 1-9.
40. Zhang RD, Fidler IJ, Price JE, (1991) Relative malignant potential of human breast carcinoma cell lines established from pleural effusions and a brain metastasis. Invasion Metastasis 11: 204-215.
41. Holen I, Coleman RE, (2010) Anti-tumour activity of bisphosphonates in preclinical models of breast cancer. Breast Cancer Res 12: 214.
42. Shi B, Vinyals A, Alia P, Broceno C, Chen F, et al. (2006) Differential expression of MHC class II molecules in highly metastatic breast cancer cells is mediated by the regulation of the CIITA transcription Implication of CIITA in tumor and metastasis development. Int J Biochem Cell Biol 38: 544-562.
43. Bhat KP, Turner JD, Myers SE, Cape AD, Ting JP, et al. (2008) The 19S proteasome ATPase Sug1 plays a critical role in regulating MHC class II transcription. Mol Immunol 45: 2214-2224.
44. Wong AW, Ghosh N, McKinnon KP, Reed W, Piskurich JF, et al. (2002) Regulation and specificity of MHC2TA promoter usage in human primary T lymphocytes and cell line. J Immunol 169: 3112-3119.
45. Truax AD, Greer SF, (2012) ChIP and Re-ChIP Assays: Investigating Interactions Between Regulatory Proteins, Histone Modifications, and the DNA Sequences to Which They Bind. Methods Mol Biol 809: 175-188.
46. Satoh A, Toyota M, Ikeda H, Morimoto Y, Akino K, et al. (2004) Epigenetic inactivation of class II transactivator (CIITA) is associated with the absence of interferon-gamma-induced HLA-DR expression in colorectal and gastric cancer cells. Oncogene 23: 8876-8886.
47. Rybtsova N, Leimgruber E, Seguin-Estevez Q, Dunand-Sauthier I, Krawczyk M, et al. (2007) Transcription-coupled deposition of histone modifications during MHC class II gene activation. Nucleic Acids Res 35: 3431-3441.
48. Kretsovali A, Agalioti T, Spilianakis C, Tzortzakaki E, Merika M, et al. (1998) Involvement of CREB binding protein in expression of major histocompatibility complex class II genes via interaction with the class II transactivator. Mol Cell Biol 18: 6777-6783.
49. Chan HM, La Thangue NB, (2001) p300/CBP proteins: HATs for transcriptional bridges and scaffolds. J Cell Sci 114: 2363-2373.
50. Bannister AJ, Kouzarides T, (2004) Histone methylation: recognizing the methyl mark. Methods Enzymol 376: 269-288.
51. Humphreys JS, Lyle D, Wakerman J, Chalmers E, Wilkinson D, et al. (2000) Roles and activities of the Commonwealth Government University Departments of Rural Health. Aust J Rural Health 8: 120-133.
52. Morris AC, Spangler WE, Boss JM, (2000) Methylation of class II trans-activator promoter IV: a novel mechanism of MHC class II gene control. J Immunol 164: 4143-4149.
53. Price JE, (1990) The biology of metastatic breast cancer. Cancer 66: 1313-1320.
54. van den Elsen PJ, Gobin SJ, van der Stoep N, Datema G, Vietor HE, (2001) Transcriptional control of MHC genes in fetal trophoblast cells. J Reprod Immunol 52: 129-145.
55. Croce M, De Ambrosis A, Corrias MV, Pistoia V, Occhino M, et al. (2003) Different levels of control prevent interferon-gamma-inducible HLA-class II expression in human neuroblastoma cells. Oncogene 22: 7848-7857.
56. Brocker EB, Suter L, Sorg C, (1984) HLA-DR antigen expression in primary melanomas of the skin. J Invest Dermatol 82: 244-247.
57. Concha A, Esteban F, Cabrera T, Ruiz-Cabello F, Garrido F, (1991) Tumor aggressiveness and MHC class I and II antigens in laryngeal and breast cancer. Semin Cancer Biol 2: 47-54.
58. de Waard-Siebinga I, Kool J, Jager MJ, (1995) HLA antigen expression on uveal melanoma cells in vivo and in vitro. Hum Immunol 44: 111-117.
59. Ruiz-Cabello F, Klein E, Garrido F, (1991) MHC antigens on human tumors. Immunol Lett 29: 181-189.
60. Maiorana A, Cesinaro AM, Fano RA, Collina G, (1995) Expression of MHC class I and class II antigens in primary breast carcinomas and synchronous nodal metastases. Clin Exp Metastasis 13: 43-48.
61. Sotiriadou R, Perez SA, Gritzapis AD, Sotiropoulou PA, Echner H, et al. (2001) Peptide HER2(776-788) represents a naturally processed broad MHC class II-restricted T cell epitope. Br J Cancer 85: 1527-1534.
62. Gorelik E, Kim M, Duty L, Henion T, Galili U, (1993) Control of metastatic properties of BL6 melanoma cells by H-2Kb gene: immunological and nonimmunological mechanisms. Clin Exp Metastasis 11: 439-452.
63. Walter W, Lingnau K, Schmitt E, Loos M, Maeurer MJ, (2000) MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance? Br J Cancer 83: 1192-1201.
64. Collett K, Eide GE, Arnes J, Stefansson IM, Eide J, et al. (2006) Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin Cancer Res 12: 1168-1174.
65. Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, et al. (2006) EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 24: 268-273.
66. Raman JD, Mongan NP, Tickoo SK, Boorjian SA, Scherr DS, et al. (2005) Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder. Clin Cancer Res 11: 8570-8576.
67. Xiao Y, (2011) Enhancer of zeste homolog 2: A potential target for tumor therapy. Int J Biochem Cell Biol.
68. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, et al. (2003) EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A 100: 11606-11611.
69. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, et al. (2002) The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419: 624-629.
70. Reijm EA, Jansen MP, Ruigrok-Ritstier K, van Staveren IL, Look MP, et al. Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer. Breast Cancer Res Treat.
71. Yan X, Shen H, Jiang H, Zhang C, Hu D, et al. (2006) External Qi of Yan Xin Qigong differentially regulates the Akt and extracellular signal-regulated kinase pathways and is cytotoxic to cancer cells but not to normal cells. Int J Biochem Cell Biol 38: 2102-2113.
72. Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, et al. (2006) The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439: 871-874.